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Vitamin D deﬁciency is linked to accelerated decline in lung function, increased inﬂam-
mation, and reduced immunity in chronic lung diseases. Epidemiological studies have
suggested that vitamin D insufﬁciency is associated with low lung function in susceptible
subjects who are exposed to higher levels of environmental agents (airborne particulates).
Recent studies have highlighted the role of vitamin D and vitamin D receptor (VDR) in reg-
ulation of several genes that are involved in inﬂammation, immunity, cellular proliferation,
differentiation,andapoptosis.VitaminDhasalsobeenimplicatedinreversalofsteroidresis-
tance and airway remodeling, which are the hallmarks of chronic obstructive pulmonary
disease (COPD) and severe asthma. VDR protein level is decreased in lungs of patients
with COPD. VDR deﬁcient mice develop an abnormal lung phenotype with characteris-
tics of COPD, such as airspace enlargement and decline in lung function associated with
increased lung inﬂammatory cellular inﬂux, and immune-lymphoid aggregates formation.
DietaryvitaminDmayregulateepigeneticevents,inparticularongeneswhichareresponsi-
ble for COPD susceptibility. Active metabolite of vitamin D, 1,25-dihydroxyvitamin D3 plays
an essential role in cellular metabolism and differentiation via its nuclear receptor (VDR)
that cooperates with several other chromatin modiﬁcation enzymes (histone acetyltrans-
ferasesandhistonedeacetylases),therebymediatingcomplexepigeneticeventsinvitamin
D signaling and metabolism.This review provides an update on the current knowledge and
understanding on vitamin D, and susceptibility of chronic lung diseases in relation to the
possible role of epigenetics in its molecular action. Understanding the molecular epige-
netic mechanism of vitamin D/VDR would provide rationale for dietary vitamin D-mediated
intervention in prevention and management of chronic lung diseases linked with vitamin
D deﬁciency.
Keywords: vitamin D receptor, vitamin D, air pollutants, inﬂammation, epigenetics, asthma, COPD
INTRODUCTION
In recent years, vitamin D insufﬁciency has been on the rise in
generalpopulationthroughouttheworld(Gindeetal.,2009).Vit-
amin D deﬁciency is linked to decline in lung function, increased
inﬂammation,andreducedimmunity(Janssensetal.,2009;Liton-
jua, 2009; Kumar et al., 2011). Epidemiological studies have fur-
ther suggested that vitamin D insufﬁciency is associated with
poor lung function in susceptible populations, particularly in
patients with asthma and chronic obstructive pulmonary dis-
ease (COPD; Gilbert et al., 2009; Chishimba et al., 2010; Forrest
and Stuhldreher, 2011; Kunisaki et al., 2011) who are exposed
to higher levels of air pollutants (airborne particulates). These
susceptible individuals may develop frequent exacerbations,rapid
decline in lung function, and exercise capacity (Ferrari et al.,
2010; Janssens et al., 2010; Newnham et al., 2010; Hansdottir and
Monick, 2011).
Recent studies have shown that vitamin D has pleiotropic pro-
tective effects (Lin and White, 2004; Chishimba et al., 2010).
1,25(OH)2D3 (1,25-dihydroxyvitamin D3), an active metabolite
of vitamin D is also a potent regulator of the immune response in
Th1 cell-directed diseases (Cantorna, 2000; White, 2008). Ligand
binding activates vitamin D receptor (VDR), a steroid hormone
superfamily of nuclear receptors, which then binds to speciﬁc
genomic sequences in the promoter regions of target genes (vita-
min D response elements), and thus recruits transcription factors
and co-regulatory molecules on promoters to activate or suppress
gene transcription (Dusso, 2003). Therefore, it is possible that
epigenetic chromatin remodeling events might be important in
the regulation of vitamin D-mediated gene expression involved in
various cellular functions.We have recently shown thatVDR deﬁ-
ciencyinvokeslunginﬂammationandalterationsinlungfunction
(Sundar et al., 2011). Hence, understanding the molecular mech-
anisms of dietary vitamin D for the treatment of lung disease and
their exacerbations are an emerging area of research (Lehouck
et al., 2011). The aim of this review is to highlight the immune-
inﬂammatoryresponseslinkedtoepigeneticchromatinalterations
by dietary vitamin D, and the importance and role of dietary
vitamin D in modulating chronic lung diseases augmented by
exposure to cigarette smoke and environmental agents (airborne
particulates).
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VITAMIN D DEFICIENCY AND LUNG FUNCTION
The active form of vitamin D, 1,25(OH)2D3 (1,25-dihydroxy-
vitamin D3) is critical for immune regulation, and deﬁciency
of vitamin D has been linked to several chronic diseases in sus-
ceptible population exposed to airborne particulates (Cantorna,
2000; Bouillon et al., 2008b; Dogan et al., 2009; Herr et al., 2011).
Janssens et al. (2011) explained several interesting aspects on the
role of vitamin D in COPD, such as the prevalence and determi-
nantsofvitaminDdeﬁciencyinCOPD,roleofvitaminDinCOPD
andosteoporosis,vitaminDpathwaylinkingairwaysandsystemic
inﬂammation in COPD. Furthermore, several recent studies have
correlated the dietary status of vitamin D with the pathogenesis
of chronic lung diseases, such as the COPD and asthma (Janssens
et al., 2009; Sutherland et al., 2010; Herr et al., 2011; Kumar et al.,
2011). The Third National Health and Nutrition Examination
Survey (NHANES) study showed a strong relationship between
serum levels of 25-hydroxyvitamin D and pulmonary function,as
assessed by FEV1 and FVC in susceptible US populations living
in urban areas (Black and Scragg, 2005). Another cross-sectional
study from Spain in hospitalized adult COPD patients revealed
the similar results on decreased vitamin D intake based on dietary
assessment of vitamin D status (De Batlle et al., 2009). However,
a recent study reported by Shaheen et al. in an older adult UK
population (the Hertfordshire Cohort study) did not show a posi-
tive correlation between serum 25(OH)D concentrations (dietary
vitamin D intake) and lung function in spirometrically deﬁned
COPD patients. This study concluded that vitamin D is not an
important determinant of adult lung function or COPD in the
general UK population (Shaheen et al.,2011).
Vitamin D-binding protein has immunomodulatory func-
tions pertinent to the lung, and is associated with activation of
macrophages and neutrophil chemotaxis (Chishimba et al., 2010;
Wood et al., 2011). Several reports have shown the functional rel-
evance of vitamin D-binding protein gene (GC; group-speciﬁc
component) polymorphism association with COPD (Schellen-
berg et al., 1998; Ohkura et al., 2006; Janssens et al., 2010).
Furthermore,recentepidemiologicalreportshaveemphasizedthe
association of low serum levels of vitamin D in severe asthmatics
and COPD patients with steroid use, and patients with reduced
glucocorticoid response (Franco et al., 2009; Janssens et al., 2009;
Searing et al., 2010). However, the role of dietary vitamin D
supplementation in response to cigarette smoke and environmen-
tal agents (airborne particulates) on lung mechanics/functions
andlungimmune-inﬂammatorycellularregulationviaepigenetic
chromatin modiﬁcations is less understood.
VITAMIN D REGULATION OF IMMUNE AND INFLAMMATORY
RESPONSES IN CHRONIC LUNG DISEASES
Smoking alters vitamin D metabolism in the lungs (Hansdot-
tir et al., 2010b), and dietary vitamin D regulates several genes
that are involved in immune response, inﬂammation, cellu-
lar proliferation, differentiation, and apoptosis (Holick, 2007;
Figure1).Recentstudieshavehighlightedthephysiologicalimpli-
cations of vitamin D intake/supplementation to improve innate
immune response against respiratory pathogens as well as to
enhance respiratory health in subjects with vitamin D deﬁciency/
insufﬁciency (Holick and Chen,2008;Hughes and Norton,2009).
1,25 (OH)2D3 is a direct regulator of antimicrobial peptides,such
as cathelicidin (camp) and defensin β2( defβ2) genes that are dri-
ven by vitamin D response elements (VDRE)-containing promot-
ers,revealing the potential therapeutic role of vitamin D3 analogs
against opportunistic infections, including the infections in the
respiratorytractswhichoccursinpatientswithCOPDsusceptible
to exacerbations (Wang et al., 2004). The active vitamin D gener-
ated in the lung plays a vital role in pulmonary immune response.
Vitamin D in airway epithelium regulates VDR-mediated gene
expression to recognize and kill pathogens via a mechanism
involving the TLR co-receptor CD14 and antimicrobial peptides
(Hansdottir et al., 2008). Furthermore, during the viral infection
in airway epithelium, 1,25D (1,25-dihydroxyvitamin D) modu-
latestheexpressionofNF-κB-mediatedinﬂammatorychemokines
and cytokines (Hansdottir et al., 2010a). VDR deﬁcient (VDR–/–)
miceshowedresistancetoLPS-inducedairwayinﬂammationeven
though pathogenic T cells were primed and activated which sup-
ports the fact that 1,25(OH)2D3 and VDR in the lung play an
important role in response to inﬂammatory signals mainly, the
innate immune response (Wittke et al.,2007).VDR–/– mice failed
to develop airway inﬂammation and airway hyperresponsive-
ness, suggesting that vitamin D could play an important role in
Th2-driven lung inﬂammation (Wittke et al., 2004, 2007).
ThelevelsofVDRareshowntobesigniﬁcantlylowerinthelung
tissuesfrompatientswithCOPDcomparedwithsmokers(Sundar
et al., 2011). The lung phenotypic, physiological characteristics,
and associated key signaling molecules, and respiratory mechan-
ics are recently studied in the lungs of VDR–/– mice (Sundar et al.,
2011). VDR–/– mice showed a signiﬁcant increase in neutrophil
inﬂux in BAL ﬂuid and increased macrophage inﬂux into the
lung interstitium compared to WT mice (Sundar et al., 2011).
The progression of COPD severity has been associated with cellu-
larinﬁltrationof inﬂammatoryimmunecellsinthesmallairways.
Vitamin D functions to generate anti-inﬂammatory cytokines to
protect the host environment against invading microbes from the
external environment (Adams and Hewison, 2008). 1,25(OH)2D
is produced by the VDR-macrophage interaction to modulate
innate immunity against microbial agents. VDR-expressing T-
and B-lymphocytes modulate adaptive immunity, thus minimiz-
ing inﬂammation and autoimmune diseases (Adorini et al., 2004;
Liu et al., 2006; Adams and Hewison, 2008). This may have
implications in severity or exacerbations of asthma and COPD.
Neutrophilic granulocytes and macrophages, which belong to
the innate immune system,are the key inﬂammatory cells that are
known to play an important role in the pathogenesis of COPD.
This has been conﬁrmed by several animal studies demonstrat-
ing the importance of these immune cells in the induction and
development of cigarette smoke-mediated chronic lung inﬂam-
mation and emphysema (Yao et al., 2008; Rajendrasozhan et al.,
2010). Several studies have highlighted the facts that the progres-
sion and severity of COPD are associated with increasing cellu-
lar inﬁltration of airways by innate and adaptive inﬂammatory
immunecells(polymorphonuclearleukocytes,macrophages,lym-
phocyte subtypes CD4+ and CD8+ T cells, and B-lymphocytes).
These immune-inﬂammatory cells form an aggregate as large vol-
ume together with the pool of inﬂammatory cells as lymphoid
follicles in severe cases of COPD (Hogg et al., 2004; van der
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FIGURE 1 | Role of vitamin D/VDR in environmental agent-mediated
deregulation of cellular and molecular functions. Environmental agents
such as cigarette smoke, particulate matter (less than 10μm, PM10), ultraﬁne
particles, inhaled oxidants, ozone, and aldehydes activate vitamin D receptor
and affects different downstream cellular and molecular targets as a result of
vitamin D-mediated deregulation.The major cellular and molecular function
affected due to vitamin D/VDR deregulation includes: calcemic effects,
antimicrobial peptide gene activation, tissue remodeling, immune modulation
and autoantibody production, muscle function, steroid efﬁcacy, and
epigenetic regulation.
Strate et al., 2006). All of these processes including regulation of
innateimmuneaswellasinﬂammatoryresponsesareregulatedby
vitamin D (Figure 1).
Pulmonary inﬂammatory response (inﬁltration of neutrophils
and macrophages) plays a central role in the etiology of COPD as
evidencedinemphysematouslungof smokersandmouseexposed
to cigarette smoke showing airspace enlargement (Barnes et al.,
2003; Yao et al., 2008; Rajendrasozhan et al., 2010). Immune-
inﬂammatory cells release numerous mediators that can cause
airwayconstrictionandremodeling. Thesecellsalsoproducepro-
teases (elastases, cathepsins, granzymes, and MMPs) that could
destroy the lung parenchyma. Changes in the levels of these
mediators are associated with activation of NF-κB in the lung
(Caramori et al., 2003; Rajendrasozhan et al., 2008). Site-speciﬁc
post-translationalmodiﬁcations(PTMs),suchasphosphorylation
and acetylation of RelA/p65 play an important role in the activa-
tion of NF-κB and cigarette smoke-mediated lung inﬂammation
(Chen et al., 2005; Yang et al., 2007). The role of VDR in regu-
lation of inﬂammation has been recently demonstrated using the
VDR deﬁcient mouse embryonic ﬁbroblast cells.Ablation of VDR
leads to reduction in the protein levels of IκBα through protein
translation, protein–protein interaction, PTMs, and degradation
by the proteasome, thereby providing a new insight into the VDR
regulation as an inhibitor of NF-κB in inﬂammation (Wu et al.,
2010b). Recently, Wu et al. (2010a) has demonstrated the direct
involvement of intestinalVDR in suppression of bacteria-induced
NF-κBactivation.Thus,VDRplaysanimportantroleinmaintain-
ing intestinal homeostasis and in protecting host against bacterial
invasion and infection. The exact role of VDR in relation to NF-
κB signaling still remains unclear (Sun et al., 2006). VDR–/– mice
showed site-speciﬁc PTMs of NF-κB RelA/p65, increased NF-κB-
dependent pro-inﬂammatory cytokines (MCP-1 and KC) release
as well as an imbalance in levels and activities of MMPs and tis-
sue inhibitors of metalloproteinases (TIMPs) that are potentially
involved in alveolar destruction (emphysema) and extracellular
matrix remodeling in the lung (Sundar et al., 2011). Earlier stud-
ies in the heart of VDR–/– mice have demonstrated a signiﬁcant
increase in MMP-2 and MMP-9 mRNA levels (Rahman et al.,
2007;Simpsonetal.,2007).IncreasedMMPsenzymeactivityalong
with collagen deposition, contribute to cellular hypertrophy and
lung ﬁbrosis. Vitamin D modulates the expression and metabo-
lism of extracellular matrix genes inVDR–/– mice (Rahman et al.,
2007; Simpson et al., 2007). In an earlier report, 1,25(OH)2D-
deﬁciency in Klotho mutant mice with emphysema phenotype
showed, skin atrophy, and osteoporosis (Razzaque et al., 2006).
Therefore, it is speculated that vitamin D deﬁciency negatively
affects lung extracellular matrix formation and leads to cellular
senescence phenotype or smoke-induced emphysema (Black and
Scragg, 2005). Based on earlier studies, TIMPs and MMPs play
a vital role in sacculation and alveologenesis due to the fact that
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several MMPs and all the four TIMPs (i.e., TIMP1-4) are dif-
ferentially expressed during various stages of lung development
(Nuttall et al., 2004; Greenlee et al., 2007). MMPs and TIMPs are
differentially regulated in VDR deﬁcient mice. Furthermore, the
genes of these enzymes are regulated by chromatin modiﬁcations.
1,25-(OH)2Ddirectlyorindirectlymodulatesextracellularmatrix
homeostasis in tissues apart from bone, particularly in the lung
and skin tissue using the control of transforming growth factor-β
(TGF-β),MMPs,andplasminogenactivators(KoliandKeski-Oja,
1996;Boyanetal.,2007).Thereasonfordevelopmentof increased
airspace enlargement or reduced alveologenesis/alveolar septation
viaepigeneticalterationsof developmentalgenesif any,inVDR–/–
mouse remains unclear. Furthermore, the studies are needed to
understand the role of VDR in lung development over a time
course from post-partum day 1 (PP1) through PP14.
VITAMIN D REGULATION IN CO-MORBID CONDITIONS OF
CHRONIC LUNG DISEASES, AND REVERSAL OF STEROID
RESISTANCE
The immune system of VDR–/– mice show heightened response
to autoimmune diseases, such as inﬂammatory bowel disease or
type I diabetes after exposure to relevant predisposing factors
(Bouillon et al.,2008a,b).VDR–/– m i c ea r em o r ep r o n et od e v e l o p
chemocarcinogen-induced cancers including lung cancer (Bouil-
lon et al., 2008b). These mice are also reported to develop high
rennin hypertension, cardiac hypertrophy, and increased throm-
bogenicity (Rahman et al., 2007; Bouillon et al., 2008b), which
are co-morbid conditions in COPD. In humans, toll-like recep-
tor 9 (TLR9) modulates the function of 1,25(OH)2D3-induced
IL-10 secreting T regulatory cells in vivo, thus highlighting the
importance of vitamin D pathway regulation in immune func-
tion (Urry et al., 2009). Vitamin D has been shown to promote
Tregs in the presence of dexamethasone (Barrat et al., 2002). Xys-
trakis et al. (2006) showed that vitamin D induces Tregs to secrete
IL-10 in steroid resistant patients with impaired IL-10 induction
by glucocorticoids. Another study demonstrated that vitamin D
alters chemokine expression in human airway smooth muscle
cells and also inhibits gene for steroid resistance, suggesting anti-
inﬂammatory effect of vitamin D which may have therapeutic
role against steroid resistance in asthma (Banerjee et al., 2008). A
recent study investigated the relationship between 25(OH)D lev-
els in the blood and response to inhaled corticosteroids (ICS) in
severeCOPDpatientsrevealedthat25(OH)Dlevelswerenotasso-
ciatedwithvariationinshort-termFEV1 responsestoICStherapy
(Kunisaki and Rector,2011).
Inpatientswithpersistentasthma,highervitaminDlevelshave
beenlinkedwithimprovedlungfunction,decreasedairwayhyper-
responsiveness and improvement in response to glucocorticoids.
Thus, appropriate supplementation of vitamin D in patients with
asthma may improve several physiopathological conditions asso-
ciated with asthma severity and treatment response (Sutherland
et al., 2010). It is also shown that COPD patients are at high
risk of vitamin D insufﬁciency because of the less outdoor activ-
ity, increased steroid intake, as a result of impairment in renal
dysfunction and low storage capacity in muscle and fat due to
muscle wasting (Janssens et al., 2009). A recent report also rec-
ognized the association between VDR genotype polymorphism
and quadriceps strength in COPD patients, suggesting the corre-
lation of VDR in skeletal muscle impairment in COPD and other
chronic diseases (Hopkinson et al., 2008). Furthermore, vitamin
D supplementation reversed the muscle weakness demonstrating
the role of vitamin D in skeletal muscle function (Hornikx et al.,
2011). Studies from elderly patients revealed that vitamin D sup-
plementation reduced the risk of falls,and suggested that vitamin
D deﬁciency is linked to decline muscle performance and increase
infallsamongelderlypatientstreatedwithstatins(Goldsteinetal.,
2009). Recent reports in COPD patients with long-term systemic
glucocorticoids lead to increased risk for osteoporosis correlat-
ing with disease severity and low vitamin D levels (Franco et al.,
2009).Severalstudieshaveshownthefunctionalrelevanceof vita-
min D-binding protein gene (GC) polymorphism associated with
COPD (Schellenberg et al., 1998; Ohkura et al., 2006; Janssens
et al., 2010; Newnham et al., 2010). Similarly, vitamin-D-binding
protein(VDBP)genepolymorphismshavebeenshowninpatients
with asthma/COPD (Janssens et al., 2010; Newnham et al., 2010;
Sathyamurthyetal.,2010;Shenetal.,2010),highlightingthealter-
ations of overall axis of vitamin D/VDR/VDB in pathogenesis of
chronic lung diseases and their co-morbid conditions (McGowan
et al.,2010).
ThemRNAlevelsofaging-relatedgenes,suchasNF-κB,ﬁbrob-
last growth factor-23 (Fgf-23),p53,and insulin-like growth factor
1 receptor (IGF1R) are signiﬁcantly decreased in older VDR–/–
mice suggesting that ablation of VDR promotes premature aging,
cellular senescence, and vitamin D3 homeostasis is shown to reg-
ulate physiological aging (Keisala et al., 2009). It is not known
whether the deﬁciency of vitamin D has any effect on stress-
induced premature senescence/aging in smokers who develop
COPD/emphysema. Vitamin D is implicated to play a key role
in fetal lung growth, development, and maturation based on ani-
mal model and human studies (Litonjua, 2009). Evidence from
the epidemiological studies also suggested that the higher pre-
natal uptake of vitamin D protected against childhood wheezing
through its role in up-regulating antimicrobial peptides or due to
its multiple immune effects (Litonjua, 2009). Vitamin D also has
beenshowntohaveatherapeuticpotentialinalterationof steroid-
mediated smooth muscle proliferation and airway remodeling
(Clifford and Knox, 2009), which are seen in severe asthmatics
and patients with COPD during exacerbations (Litonjua, 2009;
Newnham et al., 2010; Tantisira et al., 2011). Vitamin D via VDR
mayrecruitHDAC2/SIRT1deacetylasesintransrepressorcomplex
leading to deacetylation of certain pro-inﬂammatory transcrip-
tion factor, histones, and/or upregulation of anti-inﬂammatory
cytokineIL-10(Xystrakisetal.,2006;Urryetal.,2009).Hence,vit-
amin D/VDR may have a role in regulation of nuclear chromatin
modiﬁcations.
VITAMIN D AND EPIGENETIC MECHANISMS
Histone tails are modiﬁed by an extensive group of non-
histone chromatin-associated proteins called chromatin modify-
ingenzymeswhichexistincellsasmulti-componentproteincom-
plexes (Berger, 2002). These complexes are frequently recruited
to nuclear chromatin in association with DNA-bound transcrip-
tion factors, and play a vital role in genome management and
stability. In response to environmental stresses, various covalent
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modiﬁcations in histones and associated regions of DNA occur
by binding speciﬁc factors leading to alterations in the structural
property of chromatin (Ruthenburg et al., 2007).
Histone modiﬁcations play a complex regulatory role in gene
transcription, which is inﬂuenced by a wide variety of chromatin
modiﬁcation enzymes. The PTMs of histones include: acetyla-
tion by histone acetyltransferases (HATs), deacetylation by his-
tone deacetylases (HDACs), phosphorylation by protein kinases,
methylation by histone methyltransferases (HMTs), demethy-
lation by histone demethylases (HDMs), and ubiquitination
by ubiquitination enzymes (Figure 2). Histone modiﬁcation
enzymes, their structures, mechanism, and speciﬁcities are elab-
orately reviewed earlier (Marmorstein and Trievel, 2009). These
PTMs may act alone or in concert to facilitate the activation or
repression of chromatin-mediated gene expression for various
inﬂammatory mediators, genes for cell cycle arrest, apoptosis,
senescence, antioxidants, growth factors and tumor suppressor
genes involved in COPD, and lung cancer (Berger, 2007; Guil and
Esteller, 2009). Earlier reports suggest that speciﬁc modiﬁcation
make-up constitutes a “histone code,” which is recognized via
a “decoding machinery” comprised by modiﬁcation-dependent,
and chromatin-associated polypeptides (Strahl and Allis, 2000).
The possible link for speciﬁc epigenetic modiﬁcations on pro-
inﬂammatory genes in different disease phenotype might be due
to the environment and alterations in gene expression patterns
(Jirtle and Skinner, 2007).
Post-translational modiﬁcations of histones play a key role in
epigenetic regulation of gene expression, and thus have impor-
tant implication in environmentally-mediated chronic lung dis-
eases, such as COPD and asthma (Seligson et al., 2009; Wang
FIGURE 2 |A proposed model showing the possible involvement of
vitamin D3 (1α,25-dihydroxyvitamin D3)-mediated molecular epigenetic
mechanisms in regulation of cellular and physiological processes. (A)
General mechanism showing acetylation and deacetylation of histone by
chromatin modiﬁcation. Histone acetylation correlates with active gene
transcription, and deacetylation associated with gene repression.
Demethylases along with HATs are involved in gene activation, whereas
histone trimethylation is often associated with gene repression. Vitamin
D/VDR deregulation can potentially lead to epigenetic chromatin modiﬁcations
on histones H3 and H4, which may be associated with epigenetic
modiﬁcations in chronic diseases linked with vitamin D deﬁciency. (B) Vitamin
D receptor (VDR), exist as heterodimer with retinoid X receptor (RXR), and
this complex (VDR/RXR) binds to speciﬁc genomic sequences on the
promoter regions of target genes (vitamin D response elements), and recruits
transcription factors and co-regulatory molecules to activate or suppress gene
transcription. Activation of VDR by different environmental agents along with
other co-activator proteins can lead to histone acetylation culminating
transcriptional regulation of a variety of genes involved in cellular and
molecular functions, such as: regulation of cell cycle, immune function, cell
proliferation and differentiation, growth regulation, and tumor suppression.
VDR along with co-repressor complex results in transrepression of certain
genes involved in vitamin D3 metabolism, immune function, and calcium
homeostasis. Vitamin D and VDR may be one among the key epigenetic
regulators along with chromatin modiﬁcation enzymes involved in
post-translational modiﬁcation of histones in various chronic lung diseases.
For example, VDR along with histone modiﬁcation enzymes may be involved
in acetylation, deacetylation, methylation, and demethylation, of different
epigenetically regulated target genes.
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et al.,2009). Since histones are post-translationally modiﬁed dur-
ing disease progression, the identiﬁcation of these patterns is
important for the understanding of human epigenetic marks in
disease conditions. The majority in histone modiﬁcations are
acetylation and methylation, which correlates with open chro-
matin and active gene transcription or repression (Strahl and
Allis, 2000). Abnormalities in acetylation and methylation pat-
ternsonhistones,resultingfromimbalanceof histoneacetyltrans-
ferases/deacetylases and HMTs/demethylases, are associated with
alteration in gene expression (Barlesi et al., 2007; Barnes, 2009;
Schwartz, 2010; Figure 2). However, the histone-wide/epigenome
linkingepigeneticsandairwaysdiseasearelargelyunknown.There
has been several studies supporting the fact that dietary factors
contribute to modify epigenetic marks including the dietary fac-
tors intake in utero (Davis and Uthus, 2004; Mathers et al., 2010).
Furthermore,dietaryhabitsinhumans,orinanimalsmodelsusing
experimental strategies, such as feeding high fat, low protein or
energyrestricteddietshavedemonstratedtocauseepigeneticalter-
ations from in utero to adult life (Hass et al.,1993; Lillycrop et al.,
2005; Brait et al., 2009; van Straten et al., 2010; Widiker et al.,
2010). Diet-induced epigenetic changes and their involvement in
human health including in utero by vitamin D metabolism are the
interests of current research (Karlic and Varga, 2011; McKay and
Mathers, 2011).
Various recent studies have shown the evidence that mul-
tifunctional enhancers regulate VDR gene transcription, and
1,25(OH)2D3 induce the accumulation of VDR and up-regulate
histone H4 acetylation at conserved regions in the human VDR
gene(Zellaetal.,2010).VDR/RXRdimerinteractswithtranscrip-
tional co-activators, such as the HATs to regulate transcription
(Fujiki et al., 2005). Vitamin D, VDR, and other nuclear recep-
tors (RXR and GR) interact with other epigenetically regulated
nuclear receptors mediating speciﬁc response to nutrients and
metabolism (Karlic and Varga, 2011). Ligand-dependent HDAC-
containing complex binds with relB promoter and VDR in den-
dritic cells (DC). Experimental evidence showed that HDAC3 is
involved in negative regulation of relB in DC stimulated with
LPS resulting in dissociation of VDR/HDAC3 from the relB pro-
moter. This demonstrates the importance of vitamin D-mediated
chromatin remodeling in regulation of DC function (Dong et al.,
2005). Epigenetic role of 1,25(OH)2D3-mediated IL-12B repres-
sionwasdemonstratedbythequantitativeChIPassay.VDRandits
partner RXR ligand recruits co-repressor complex [NCoR2/silent
mediator for retinoid and thyroid hormone receptors (SMRT)]
along with HDAC3 resulting in decreased acetylation of histone
H4 and increased trimethylation of histone H3 (H3K27me3) on
the IL-12B promoter and its transcription start site (TSS; Gyn-
ther et al., 2011). Recently, An et al. (2010) showed that VDR
interacts with FOXO (Forkhead box O) proteins and its regula-
tor SIRT1, and 1,25D and stimulates SIRT1- and phosphatase-
dependent dephosphorylation and activation of FOXO protein
function. FOXOs have been shown to be regulated by VDR (An
et al., 2010). Calcitriol-mediated activation of VDR further aug-
ments the recruitment of FOXO3A and FOXO4 to the promoters
of VDR target genes (An et al., 2010). Additionally, FOXO pro-
teins also interact with other epigenetic regulators, such as SIRT1
(Voelter-MahlknechtandMahlknecht,2010).VDRinhibitsNF-κB
function through SIRT1 and 1,25D signaling, suggesting the role
of 1,25D-mediateddeacetylationof NF-κBthroughitsinteraction
with SIRT1 (Lavu et al.,2008). This may have implications in epi-
geneticregulationofsteroidresistanceandinﬂammatoryresponse
in patients with asthma and COPD where vitamin D insufﬁ-
ciency/deﬁciencyoccurs.Inaddition,thismayplayaroleinepige-
netic changes associated with vitamin D insufﬁciency/deﬁciency
inadditiontohighmethyldonordietandenvironmentaleffectsin
utero which would result in susceptibility to chronic lung diseases
later in adult life.
Vitamin D receptor and vitamin D regulate p21(waf1/cip1) gene
whichisinvolvedincellcyclearrest(Liuetal.,1996).Arecentstudy
showed that VDR induced regulation of p21(waf1/cip1) expression
andcellcyclearrestwhichislinkedtoVDR-governedfeed-forward
loop including interplay of histone modiﬁcations (H3K9ac and
H3K27me3; Thorne et al., 2011). Another recent report provided
the evidence that VDR-responsive genes, such as the tumor sup-
pressor C/EBP, could be re-induced by treating the cells with
5 deoxy-azacytidine(AZA;Mariketal.,2010).TheVDR-mediated
positiveandnegativegeneregulationbyco-repressors[SMRT,NR
co-repressors (NCoR)], co-activators [CBP/p300, steroid recep-
tor co-activators (SRCs)], and chromatin remodeling complex
(SWI/SNF) were reviewed earlier (Bouillon et al., 2008b; Kar-
lic and Varga, 2011). These studies highlight the role of vitamin
D/VDR in regulation of epigenetic modiﬁcations on promoters
of genes, such as p21(waf1/cip1) and C/EBP, and thereby regulat-
ing cellular senescence and differentiation. Hence, understanding
the epigenetics of vitamin D and VDR on chromatin modiﬁca-
tions and modulation of pro-inﬂammatory genes, cell cycle, and
antimicrobialgeneexpressionwouldprovideknowledgeformole-
cularepigeneticfunctionsof vitaminDinmanagementof chronic
inﬂammatory lung diseases. This may be possible by understand-
ing the epigenetic role of vitamin D and VDR in mouse models
andevaluatethesubsetsof keyhistonemodiﬁcationmarkscaused
in response to environmental exposures.
FUTURE PERSPECTIVES OF EPIGENETIC-BASED VITAMIN D
THERAPY IN CHRONIC LUNG DISEASES
Vitamin D deﬁciency/insufﬁciency is an important global public-
health problem due to low serum levels of vitamin D either due
to its low intake or reduced biosynthesis (Janssens et al., 2009).
Epidemiological studies have suggested a strong correlation of
low serum concentrations of 25-hydroxy vitamin D with decline
in pulmonary function in susceptible population (asthma and
COPD) exposed to environmental airborne particulates (Black
and Scragg, 2005; Gilbert et al., 2009; Hughes and Norton, 2009;
Kunisaki et al., 2011). A recent study on vitamin D status in
patients with COPD who participate in pulmonary rehabilita-
tion (PR) revealed an association between vitamin D deﬁciency
and higher dropout rates and smaller improvement in functional
capacity. The potential relationship between vitamin D deﬁciency
and muscle function in PR, however, are not known (Ringbaek
et al., 2011). The beneﬁcial effect of vitamin D based on its newly
discoveredactionfortherapeuticinterventioninchroniclungdis-
ease and other health effects are reviewed earlier (Bikle, 2009,
2010; Clifford and Knox,2009;Adams and Hewison,2010; Rosen,
2011).
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Vitamin D and VDR regulate several cellular processes, such
as inﬂammation, proliferation, senescence, differentiation, and
apoptosis(Holick,2007).Recentstudieshavehighlightedthephys-
iological implications of dietary vitamin D in improvement of
innate immune and inﬂammatory responses against respiratory
pathogens, opportunistic infections, and environmental agents
(Wang et al., 2004; Holick and Chen, 2008; Herr et al., 2011;
Zosky et al., 2011). The levels of VDR are signiﬁcantly decreased
in lung tissues of COPD patients (Sundar et al., 2011). VDR deﬁ-
cient/knockoutmicedevelopedCOPD-phenotypeimplicatingthe
roleofVDRinpathogenesisofchroniclungdiseases(Sundaretal.,
2011). Several studies have also highlighted the importance of vit-
amin D supplementation and VDR with steroid resistance and
exacerbations in patients with COPD and asthma (Searing et al.,
2010; Sutherland et al., 2010). Quint and Wedzicha (2010) in a
recent editorial highlighted several distinct reports that link vita-
minDdeﬁciencyandCOPD.Furthermore,adequateclinicaltrials
assessingspeciﬁcclinicaloutcomesusingvitaminDsupplementa-
tions in COPD may facilitate in understanding the role of vitamin
D in COPD and the mechanisms by which increasing vitamin D
levels from the normal range would inﬂuence the natural history
of COPD (Quint and Wedzicha, 2010). Current research on vit-
amin D is exciting, as the reports on vitamin D supplementation
using animal models and human clinical trials start to unfold,
and will shed light on the hidden molecular epigenetic regula-
tory mechanisms of vitamin D and VDR in respiratory diseases.
The research on role of vitamin D in regulation of epigenetics
in various cellular functions is primitive, but will gain credence
after the completion of several clinical trials that are currently
in progress, testing the protective role of vitamin D in the pre-
vention and treatment of chronic lung diseases, such as asthma
and COPD (www.clinicaltrials.gov). Hence, studies on molecu-
lar epigenetic mechanisms of dietary vitamin D in lung cellular
function (senescence, apoptosis, autophagy, proliferation, phago-
cytosis) and disease severity (immune-inﬂammatory responses,
steroid resistance, host-defense) particularly in response to envi-
ronmentalagentswouldproviderationaleindevelopmentof pos-
sible interventions in the management and prevention of chronic
lung diseases and its susceptibility to exacerbations by dietary vit-
amin D supplementation (Lehouck et al., 2011). Understanding
the key epigenetic mechanisms involved in vitamin D-mediated
chromatin modiﬁcations (regulation of HDACs/SIRT1, histone
acetylation/methylation/demethylation) would provide rationale
fortheepigenetic-basedtherapybyvitaminDsupplementationin
management and prevention of chronic lung diseases.
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